Back to Search
Start Over
Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor.
- Source :
-
ACS medicinal chemistry letters [ACS Med Chem Lett] 2016 Sep 12; Vol. 7 (10), pp. 933-938. Date of Electronic Publication: 2016 Sep 12 (Print Publication: 2016). - Publication Year :
- 2016
-
Abstract
- The aspartic proteinase renin is an attractive target for the treatment of hypertension and cardiovascular/renal disease such as chronic kidney disease and heart failure. We introduced an S1' site binder into the lead compound 1 guided by structure-based drug design (SBDD), and further optimization of physicochemical properties led to the discovery of benzimidazole derivative 10 (1-(4-methoxybutyl)- N -(2-methylpropyl)- N -[(3 S ,5 R )-5-(morpholin-4-yl)carbonylpiperidin-3-yl]-1 H- benzimidazole-2-carboxamide hydrochloride, TAK-272) as a highly potent and orally active renin inhibitor. Compound 10 demonstrated good oral bioavailability (BA) and long-lasting efficacy in rats. Compound 10 is currently in clinical trials.
Details
- Language :
- English
- ISSN :
- 1948-5875
- Volume :
- 7
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- ACS medicinal chemistry letters
- Publication Type :
- Academic Journal
- Accession number :
- 27774132
- Full Text :
- https://doi.org/10.1021/acsmedchemlett.6b00251